Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.17.
A number of brokerages recently weighed in on TSHA. Canaccord Genuity Group boosted their price objective on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, June 3rd. JMP Securities boosted their price objective on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 29th. Chardan Capital boosted their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th.
Check Out Our Latest Stock Report on TSHA
Taysha Gene Therapies Price Performance
NASDAQ TSHA traded up $0.05 during midday trading on Monday, hitting $2.59. The company had a trading volume of 3,484,472 shares, compared to its average volume of 2,951,962. The company has a market capitalization of $555.97 million, a PE ratio of -7.62 and a beta of 0.97. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.77. The firm has a 50-day moving average price of $2.57 and a 200-day moving average price of $1.96. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $3.31.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same quarter last year, the company posted ($0.10) EPS. As a group, analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, major shareholder Paul B. Manning acquired 750,000 shares of Taysha Gene Therapies stock in a transaction on Friday, May 30th. The stock was acquired at an average cost of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the acquisition, the insider owned 2,841,704 shares in the company, valued at approximately $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.78% of the company's stock.
Institutional Investors Weigh In On Taysha Gene Therapies
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its position in shares of Taysha Gene Therapies by 7.0% in the first quarter. Rhumbline Advisers now owns 205,462 shares of the company's stock worth $286,000 after buying an additional 13,383 shares in the last quarter. Octagon Capital Advisors LP increased its stake in Taysha Gene Therapies by 2.4% in the first quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company's stock valued at $14,873,000 after acquiring an additional 250,000 shares during the last quarter. Granahan Investment Management LLC increased its stake in Taysha Gene Therapies by 0.3% in the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock valued at $2,281,000 after acquiring an additional 4,412 shares during the last quarter. AQR Capital Management LLC increased its stake in Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company's stock valued at $150,000 after acquiring an additional 82,545 shares during the last quarter. Finally, ADAR1 Capital Management LLC increased its stake in Taysha Gene Therapies by 500.0% in the first quarter. ADAR1 Capital Management LLC now owns 1,066,309 shares of the company's stock valued at $1,482,000 after acquiring an additional 888,602 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.
About Taysha Gene Therapies
(
Get Free ReportTaysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Further Reading

Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.